[1] |
SHEN Mengqiu, LI Ming, WANG Jiayu, GAN Ge, LIU Pengcheng, SUN Jun.
Sampling Investigation of Current Situalion of Pharmacovigilance in Pharmaceutical Manufacturers in Jiangsu Province
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 133-137.
|
[2] |
ZHAO Xia, LENG Meiling, WANG Peng, LI Xinling, CAO Lujuan, TIAN Chunhua, LIU Cuili.
Research on Current Status and Countermeasures of Information Collection on Adverse Drug Reactions by Drug Manufacturers from Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 652-657.
|
[3] |
FENG Hong-yun, WU Gui-zhi, FAN Yan, DONG Duo.
Analysis of Drug Manufacturer on Post-marketing Drug Risk Monitoring and Management Status in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(1): 16-19.
|
[4] |
CHANG Yun-feng, HAO Lei, ZHANG Xiao-jian, LI Xue-li, GAO Han, LI Jun-shan.
To compare the quality of Schisandra formula particles from different manufacturers
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 278-282.
|
[5] |
PENG Li-li, FAN Yan, LIU Wei, GUO Xue, HU Jun.
How Drug Manufacturers to Establish Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(11): 666-670.
|
[6] |
SUN Jun, HUANG Qian-qian, GAN Ge, WANG Jia-yu.
Discussion on the Strategy of Drug Manufacturers to Deal with the Adverse Drug Event Clustering Signal
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(11): 671-674.
|
[7] |
ZHENG Li-jia, ZHAO Yan, DONG Fang.
Medical Device Adverse Events Monitoring and Risk Analysis on Ventilators
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 503-504.
|
[8] |
PENG Li-Li, FAN Yan, LI Xin-ling.
Discussion on How Drug Manufacturers Fulfill the First Person Responsibilities of Post-marketing Drug Safety
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(3): 159-161.
|
[9] |
LI Ning, REN Jing-tian.
Discussion on How Drug Manufacturers Report Individual Case Adverse Drug Reactions
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(2): 80-83.
|
[10] |
ZHANG Xue-mei, GUO Jia-dong, FENG Bian-ling, YANG Shi-min.
Investigation on Work State of Adverse Drug Reaction Reporting in Some West Provinces
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(12): 740-743.
|
[11] |
.
TIAN Ke-ren1 GAO Jing2 MIU Jian3 WAN Kai-hua2 YU Chao2 ZHOU Juan2 XU Jin2 LI Sui2
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(5): 285-287.
|
[12] |
REN Jing-tian, ZHENG Wen-ke, ZHANG Jun-hua, LEI Xiang, YANG Le, GUO Xiao-xin, SHANG Hong-cai, DU Xiao-xi.
Role of Drug Manufacturers in Post-marketed Drug Risk Management
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(2): 88-93.
|
[13] |
SUN Jun, WEI Zhen, LI Ming.
Investigation of Pharmaceutical Manufacturers' Establishments on Management System for Monitoring and Reporting Adverse Drug Reactions
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(1): 8-11.
|
[14] |
DONG Duo, SUN Li-hua.
Study of Guideline for Drug Man ufacturer on Adverse Drug Reaction Reporting and Monitoring with Delphi Method
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(9): 523-526.
|
[15] |
YU Wen-wen, ZHAO Yan ,QING Shan.
Analysis of Adverse Events and Related Factors of Implantable Cardiac Pacemaker
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(6): 366-368.
|